Company Announcements

Studies leverage company’s Afirma Genomic Resource for Intelligent Discovery (GRID), world’s largest molecular database for thyroid nodules

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 9, 2025-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at the Westin Kierland in Scottsdale, Ariz. The large number of abstracts stems from Veracyte’s extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles—which is the largest dataset of its kind in thyroid cancer research—and its novel Afirma GRID (Genomic Resource for Intelligent Discovery) research tool. The company makes Afirma GRID available to eligible researchers seeking to further elucidate the molecular drivers of thyroid cancer and inform innovations in patient care.

“The breadth and depth of Afirma-focused abstracts being presented at the ATA meeting stem from our unique assets and capabilities, combined with our commitment to collaborating with the research community to advance scientific understanding of thyroid nodules and thyroid cancer,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology. “Ultimately, we believe that findings from such studies will lead to opportunities to further personalize care and help improve patient outcomes.”

Select abstracts leveraging Afirma GRID to be presented at the ATA meeting include:

Information about all of the Afirma-related abstracts being presented at the ATA meeting can be found here. Meeting attendees can also visit Veracyte’s booth (#301).

About the Afirma GSC

Veracyte’s flagship Afirma Genomic Sequencing Classifier (GSC) was developed with RNA whole-transcriptome-derived sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery. The Afirma GSC also includes Xpression Atlas, the largest thyroid gene variant and fusion panel available, to help inform treatment decisions for patients whose genomic test or cytopathology results are suspicious for cancer. Veracyte also enables physicians to order DNA testing of the TERT promoter gene, which is performed on the same FNA sample, to help further guide treatment decision-making. More information about the Afirma GSC can be found here.

About Afirma GRID

The Afirma GRID database is derived from the sequencing of over 21,000 expressed genes for over 350,000 patients with thyroid nodules (benign and malignant) and is used by Veracyte and its partners to contribute to continued research that helps advance understanding of thyroid tumors. Afirma GRID information is available on a Research-Use-Only basis. More information about Afirma GRID can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to Veracyte’s extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles—which the company believes is the largest in the world, and that we believe that findings from such studies will lead to opportunities to further personalize care and help improve patient outcomes. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact the Veracyte Diagnostics Platform can have on scientific advancements in cancer and, in turn, patient care. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2025. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909813969/en/

Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545

Media:
Karen Possemato
media@veracyte.com

Source: Veracyte, Inc.